Sarepta Therapeutics, Inc. SRPT Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $801.28M-27.4% | $1.1B+157% | $428.43M-55.7% | $966.78M-54.3% | ||
| $138.37M-45.0% | $251.78M-79.8% | $1.25B+22.0% | $1.02B— | ||
| $398.23M-33.8% | $601.99M+50.4% | $400.33M+86.5% | $214.63M+40.3% | ||
| $184.54M-1.8% | $187.99M-1.8% | $191.37M+17.7% | $162.55M-12.7% | ||
| $171.86M+90.0% | $90.46M+16.4% | $77.71M-48.2% | $149.89M+0.6% | ||
| $2.54B-17.4% | $3.07B+19.2% | $2.58B+0.8% | $2.56B-1.8% | ||
| $345.13M+1.4% | $340.34M+49.8% | $227.15M+26.2% | $180.04M-5.8% | ||
| $125.5M-15.4% | $148.31M+14.1% | $129.95M+100% | $64.95M+42.7% | ||
| $155.55M+94.6% | $79.92M-41.6% | $136.77M-16.1% | $162.97M-44.4% | ||
| $1.05M-99.2% | $133.16M— | $0— | —— | ||
| $3.35B-15.5% | $3.96B+21.4% | $3.26B+4.4% | $3.13B-0.6% | ||
| $280.84M+31.0% | $214.44M+30.0% | $164.92M+72.0% | $95.88M+24.9% | ||
| $11.39M-15.4% | $13.47M-24.5% | $17.85M-95.7% | $419M+2,684% | ||
| $443.4M+240% | $130.26M+158% | $50.42M-43.5% | $89.24M0.0% | ||
| —— | $0-100% | $105.48M— | $0— | ||
| $11.2M-15.6% | $13.27M-25.6% | $17.85M+15.2% | $15.49M+2.9% | ||
| $83.91M-74.2% | $325M-25.6% | $437M-9.9% | $485M-15.5% | ||
| $1.1B+49.7% | $731.68M+11.9% | $653.66M+5.5% | $619.6M+36.9% | ||
| $199.38M+3.6% | $192.47M+36.5% | $140.97M+145% | $57.58M+38.7% | ||
| $1.53M-12.6% | $1.75M-41.7% | $3M+7,043% | $42K-99.6% | ||
| $2.21B-9.3% | $2.44B+1.3% | $2.41B-12.3% | $2.74B+23.6% | ||
| $0— | $0— | $0— | $0— | ||
| $11K+10.0% | $10K+11.1% | $9K0.0% | $9K0.0% | ||
| $6.04B+5.3% | $5.74B+8.2% | $5.3B+23.5% | $4.3B+3.9% | ||
| -$4.88B-15.8% | -$4.21B+5.3% | -$4.45B-13.7% | -$3.91B-21.9% | ||
| $272K+225% | -$218K-124% | $918K+155% | -$1.66M-8,220% | ||
| $25.26M— | $0— | —— | —— | ||
| $1.14B-25.3% | $1.53B+77.8% | $859.34M+123% | $384.95M-58.5% | ||
| $3.35B-15.5% | $3.96B+21.4% | $3.26B+4.4% | $3.13B-0.6% | ||
| $113.46M-58.9% | $276.26M+170% | $102.18M— | —— | ||
| $171.86M+90.0% | $90.46M+16.4% | $77.71M-48.2% | $149.89M+0.6% | ||
| $155.55M+94.6% | $79.92M-41.6% | $136.77M-16.1% | $162.97M-44.4% | ||
| $125.5M-15.4% | $148.31M+14.1% | $129.95M+100% | $64.95M+42.7% | ||
| $1.05M-99.2% | $133.16M— | $0— | —— | ||
| $125.5M-15.4% | $148.31M+14.1% | $129.95M+100% | $64.95M+42.7% | ||
| $155.55M+94.6% | $79.92M-41.6% | $136.77M-16.1% | $162.97M-44.4% | ||
| $138.37M-45.0% | $251.78M-79.8% | $1.25B+22.0% | $1.02B— | ||
| $125.5M-15.4% | $148.31M+14.1% | $129.95M+100% | $64.95M+42.7% | ||
| $155.55M+94.6% | $79.92M-41.6% | $136.77M-16.1% | $162.97M-44.4% | ||
| $83.91M-74.2% | $325M-25.6% | $437M-9.9% | $485M-15.5% | ||
| $359.66M-3.7% | $373.51M+18.6% | $315M-24.8% | $419M+54.2% | ||
| $359.66M-3.7% | $373.51M+18.6% | $315M-24.8% | $419M+54.2% | ||
| $11.39M-15.4% | $13.47M-24.5% | $17.85M+15.2% | $15.49M+2.9% | ||
| $0-100% | $47.4M+24.4% | $38.1M+3.3% | $36.9M-15.4% | ||
| $83.91M-74.2% | $325M-25.6% | $437M-9.9% | $485M-15.5% | ||
| $83.91M-74.2% | $325M-25.6% | $437M-9.9% | $485M-15.5% | ||
| $210.57M+2.3% | $205.75M-22.2% | $264.29M+262% | $73.07M+29.2% | ||
| $6.04B+5.3% | $5.74B+8.2% | $5.3B+23.5% | $4.3B+3.9% | ||
| $11K+10.0% | $10K+11.1% | $9K0.0% | $9K0.0% | ||
| $0— | $0— | $0— | $0— | ||
| $25.26M— | $0— | —— | —— | ||
| $828.97M-27.1% | $1.14B+0.4% | $1.13B-26.7% | $1.54B+40.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Sarepta Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 4.63 — current assets exceed current liabilities.
- Where does Sarepta Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Sarepta Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.